| Name | Title | Contact Details |
|---|
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle. Sapacitabine (CYC682), Cyclacel`s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel`s pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including BRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor in a Phase 1 study of patients with solid tumors with potential utility in both hematological malignancies and solid tumors. Cyclacel`s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Cyclacel Pharmaceuticals` corporate headquarters are in Berkeley Heights, New Jersey, where our business development and medical and regulatory functions are also located. The company`s primary research facility is located in Dundee, Scotland. Dundee is the main location of our translational research and preclinical activities.
Purdue Pharma L.P. is a privately held pharmaceutical company founded by physicians more than 60 years ago. We are committed to advancing the care of patients with innovative, quality products that make a positive impact on healthcare — and on lives. Purdue Pharma is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The Company is engaged in the research, development, production, and marketing of prescription medicines and over-the-counter healthcare products. We are pursuing a promising pipeline of new medications through internal research & development and strategic industry partnerships. At Purdue, we embrace our mission to find, develop, and introduce innovative medicines that meet the evolving needs of healthcare professionals, patients and caregivers.
AxxiTrials is a Irvington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MouldWorks is a Beulah, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DMC is leading the low cost sustainable transformation of multiple product markets.